Proteins

Antitumor and intercalating agent: inhibits DNA topoisomerase II.

Antitumor and intercalating agent: inhibits DNA topoisomerase II.

Elotuzumab is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural

Elsilimomab (anti-IL-6) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab (anti-IL-6) can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis

Elsilimomab (anti-IL-6) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab (anti-IL-6) can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis

Elsilimomab (anti-IL-6) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab (anti-IL-6) can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis

Elsilimomab (anti-IL-6) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab (anti-IL-6) can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis

A set of packaging is 500ml hematoxylin ➕ 500ml eosin staining solutionScope of applicationStaining of pathological tissue sectionsCharacteristic1. the nucleus was blue after staining, and the cytoplasm was pink or red.2. the staining effect is

Reversible and non-competitive CBP/p300 inhibitor.

Reversible and non-competitive CBP/p300 inhibitor.

Reversible and non-competitive CBP/p300 inhibitor.

Enapotamab (anti-AXL) is an anti-AXL/UFO reference antibody. Enapotamab (anti-AXL) can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates.